
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PKC epsilon CRISPR/Cas9 KO Plasmid (h) | sc-400358 | 20 µg | $397.00 |
PRKCE encodes protein kinase C epsilon (PKCε), a diacylglycerol-responsive serine/threonine kinase that transduces signals downstream of GPCR and receptor tyrosine kinase pathways. PKCε regulates phosphorylation networks controlling cell survival, proliferation, cytoskeletal remodeling, and directed migration, with prominent roles in MAPK/ERK, PI3K/AKT, NF-κB, and focal adhesion signaling. In human cells, PKCε also influences vesicle trafficking and mitochondrial stress responses, linking second-messenger signaling to metabolic adaptation. Dysregulated PRKCE/PKCε activity and expression have been associated with oncogenic phenotypes, therapy resistance mechanisms, and altered inflammatory signaling, making it a common target in pathway-mapping and functional genomics studies.
PKC epsilon CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PRKCE gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PRKCE together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PRKCE open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PKC epsilon protein expression.
This CRISPR knockout system enables efficient generation of PRKCE-deficient cell models for investigation of PKC epsilon signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.